Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 626-629

  Sparidans, Rolf W ^a   Durmus, Selvi ^b   Schinkel, Alfred H ^b   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

LC MS MS; PARP inhibitor; Plasma; Rucaparib

Indexed keywords

RUCAPARIB;

ACCURACY; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY; FEMALE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE; AUC; ELIMINATION HALF-LIFE; LC-MS/MS; LLOQ; LOWER LIMIT OF QUANTIFICATION; PARP; PARP INHIBITOR; PLASMA; POLY(ADP-RIBOSE) POLYMERASE; QC; QUALITY CONTROL; RUCAPARIB; SELECTED REACTION MONITORING; SRM; T(1/2);

ACETONITRILES; ANIMALS; AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, LIQUID; EDETIC ACID; FEMALE; INDOLES; MICE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; QUALITY CONTROL; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84887384454     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.10.016     Document Type: Article

References (10)

1. Gartner E.M., Burger A.M., Lorusso P.M. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J. 2010, 16:83-90.
2. Plummer R., Lorigan P., Steven N., Scott L., Middleton M.R., Wilson R.H., Mulligan E., Curtin N., Wang D., Dewji R., Abbattista A., Gallo J., Calvert H. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother. Pharmacol. 2013, 71:1191-1199.
3. U.S.National Institutes of Health ClinicalTrials.gov; Search for rucaparib 2012, http://clinicaltrials.gov/ct2/results?term=rucaparib&Search=Search (accessed 22.03.13).
4. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration, Guidance for industry; Bioanalytical method validation 2001, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm (accessed 10.12.12).
5. Sparidans R.W., Iusuf D., Schinkel A.H., Schellens J.H., Beijnen J.H. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:4090-4096.
6. Sparidans R.W., Martens I., Valkenburg-van Iersel L.B., den Hartigh J., Schellens J.H., Beijnen J.H. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 2011, 879:1851-1856.
7. Zhao M., Hartke C., Jimeno A., Li J., He P., Zabelina Y., Hidalgo M., Baker S.D. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 819:73-80.
8. Rodriguez Robledo V., Smyth W.F. A study of the analytical behaviour of selected new molecular entities using electrospray ionisation ion trap mass spectrometry, liquid chromatography, gas chromatography and polarography and their determination in serum at therapeutic concentrations. Anal. Chim. Acta 2008, 623:221-230.
9. Plummer R., Jones C., Middleton M., Wilson R., Evans J., Olsen A., Curtin N., Boddy A., McHugh P., Newell D., Harris A., Johnson P., Steinfeldt H., Dewji R., Wang D., Robson L., Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:7917-7923.
10. European Medicines Agency Guideline on validation of bioanalytical methods 2009, http://www.ema.europa.eu/pdfs/human/ewp/19221709en.pdf (accessed 10.12.12).